Upstream Bioprocessing Equipment Market Report 2026

The upstream bioprocessing equipment market size has grown rapidly in recent years. It will grow from $11.13 billion in 2025 to $12.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to growing demand for monoclonal antibodies and vaccines, increasing investment in biopharmaceutical manufacturing capacity, rising adoption of mammalian cell culture systems, expansion of contract manufacturing organizations, increasing focus on process efficiency and yield optimization.

The upstream bioprocessing equipment market size is expected to see rapid growth in the next few years. It will grow to $18.61 billion by 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing pipeline of biosimilars and biologics, growing adoption of single-use technologies, rising demand for personalized medicine production, expansion of gene and cell therapy manufacturing, increasing investment in flexible biomanufacturing facilities. Major trends in the forecast period include rising adoption of single-use bioreactor systems to reduce contamination risk and improve flexibility in biologics production, increasing demand for perfusion-based cell culture systems for continuous biologics manufacturing, growing use of modular and scalable upstream bioprocessing equipment for faster facility expansion, expanding deployment of closed-system bioprocessing solutions to enhance sterility and process efficiency, increasing integration of automated sampling and process control systems for improved upstream process consistency.

The growing need for scalable bioprocessing solutions is expected to propel the growth of the upstream bioprocessing equipment market going forward. Scalable bioprocessing solutions refer to systems and equipment that facilitate a seamless transition from research-scale production to large-scale commercial manufacturing while ensuring consistent product quality and operational efficiency. The demand for scalable bioprocessing solutions is increasing due to the rapid expansion of biologics development pipelines, which require flexible manufacturing capabilities across various production scales. Upstream bioprocessing equipment supports this demand by enabling efficient scaling of cell culture, fermentation, and production processes through advanced bioreactors and integrated systems. For instance, in January 2025, according to the BioIndustry Association, the UK biotech sector secured approximately $4.4 billion in investment, representing a 94% increase compared to the previous year. Therefore, the increasing need for scalable bioprocessing solutions is driving the growth of the upstream bioprocessing equipment market.

Leading companies operating in the upstream bioprocessing equipment market are prioritizing advancements in single-use technologies, such as integrated single-use bioreactor intensification systems, to improve production flexibility, lower contamination risks, and increase process efficiency. Integrated single-use bioreactor intensification systems are advanced bioprocessing platforms that combine disposable bioreactors with integrated cell retention and process control technologies to support high-density cell culture and continuous manufacturing without extensive cleaning requirements. For instance, in August 2023, Sartorius AG, a Germany-based life sciences company, launched an integrated Biostat STR system incorporating Repligen’s XCell Alternating Tangential Flow technology. The system includes integrated hardware and software modules with predefined control recipes, built-in process analytical technology for real-time monitoring, and enhanced cell retention capabilities that remove the need for separate control units, thereby simplifying upstream processing workflows.

In May 2023, Getinge acquired High Purity New England, Inc. for $120 million, along with an additional earn-out of up to $170 million. Through this acquisition, Getinge intends to reinforce its position in the bioprocessing market by broadening its single-use solutions portfolio and strengthening its capabilities across upstream and downstream bioprocessing applications. High Purity New England, Inc. is a US-based company offering custom single-use bioprocessing solutions and equipment that support drug discovery, upstream and downstream processing, and biopharmaceutical manufacturing.

Major companies operating in the upstream bioprocessing equipment market are Saint-Gobain Performance Plastics Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Parker-Hannifin Corporation, GE Healthcare Technologies Inc., Corning Incorporated, Lonza Group AG, Avantor Inc., Sartorius AG, Entegris Inc., Getinge AB, Waters Corporation, Eppendorf SE, ZETA GmbH, Repligen Corporation, ABEC Inc., Shelcel Biozeen Technologies Private Limited, PBS Biotech Inc., Bionet Engineering S. r. l., Meissner Filtration Products Inc., ESCO Micro Pte. Ltd., BBI-Biotech GmbH, Morimatsu International Holdings Company Limited, Adolf Kühner AG.

North America was the largest region in the upstream bioprocessing equipment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the upstream bioprocessing equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the upstream bioprocessing equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The upstream bioprocessing equipment market consists of sales of media preparation systems, filtration systems, and sterilization equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, contract manufacturing organizations, research institutes, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.